Baker Brothers Life Sciences Files Intent to Sell $2.65M in Protara Therapeutics Stock

summarizeSummary

Baker Brothers Life Sciences, a former affiliate, filed a Form 144 to sell 424,125 shares of Protara Therapeutics common stock, valued at $2.65 million, continuing a recent pattern of significant share dispositions.

check_boxKey Events

• Intent to Sell Significant Stake

  Baker Brothers Life Sciences, L.P. filed a Form 144 indicating intent to sell 424,125 shares of Protara Therapeutics common stock, with an approximate market value of $2,654,641.00.

• Continuation of Selling Pattern

  This filing is part of a series of Form 144s from Baker Brothers and its affiliates, including 667, L.P., which collectively indicate an ongoing reduction of their holdings in Protara Therapeutics, following previous filings on February 25 and 26.

• Former Affiliate Status

  The filer, Baker Brothers Life Sciences, L.P., is identified as a 'Former Affiliate' of Protara Therapeutics, Inc.

auto_awesomeAnalysis

This Form 144 indicates Baker Brothers Life Sciences, a significant institutional investor and former affiliate, intends to sell an additional 424,125 shares of Protara Therapeutics common stock, valued at approximately $2.65 million. This filing follows a series of similar Form 144s from Baker Brothers and its affiliates in late February, signaling a continued reduction of their stake in the company. While the company recently reported positive interim Phase 2 trial results, this ongoing selling pressure from a major investor could create an overhang on the stock.